A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay by Raymond, E et al.
Human telomere DNA consists of simple repeated TTAGGG-
sequences oriented 5¢ to 3¢ towards the chromosome termini
(Blackburn, 1991). The length of the terminal restriction fragment
containing the telomere repeats varies from 5 to 15 Kbp in human
somatic cells and decreases during cell senescence and aging
(Levy et al, 1992; Allsopp and Harley, 1995; Healy, 1995; Shay et
al, 1995a). Additional results support the important role of telo-
meres in chromosome stabilization, attachment to the nuclear
matrix, and effects on the expression of adjacent genes in normal
cells (Price, 1993; Gilley and Blackburn, 1994; Greider, 1994;
Healy, 1995). Convergent evidence leads to the hypothesis that
telomeric attrition could act as a cell division counter limiting the
proliferative somatic cell life span (Greider, 1993; Harrington et al,
1997; Marcand et al, 1997). Although cultured cancer cells exhibit
a relative telomeric attrition, most of them have a seemingly
unlimited proliferative lifespan.
The length of telomeres is maintained over time by telomerase,
a ribonucleoprotein containing a short RNA motif serving as a
template for synthesizing TTAGGG-sequences (Shay et al, 1994).
Telomerase activity can be measured in vitro by a primer extension
assay in which telomerase synthesizes telomeric repeats onto
oligonucleotide (TTAGGG)n primers (Shay et al, 1994). Such a
conventional telomerase assay was initially used to determine the
telomerase activity in cell lines but was not sensitive enough to
allow detection of telomerase in tissue samples from patients
because of the limited number of cells. Therefore, Kim et al
(1994) developed a more sensitive method based on a polymerase
chain reaction (PCR) technique. Using this method, designated
TRAP-assay, they demonstrated that telomerase is linked to cell
immortality, stringently repressed in normal somatic cells and
reactivated in cancer. The use of a primer with high affinity for
telomerase and PCR-amplification have increased the sensitivity
of the TRAP-assay allowing detection of telomerase in samples
containing fever than 100 tumour cells. We initially investigated
compounds that interfered with either the primer used in the TRAP
assay or with the Taq polymerase enzyme. This prompted us to
develop an assay designed to increase the telomerase signal
without the use of PCR-amplification. In previous preliminary
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Summary Telomerase is an RNA-dependent polymerase that synthesizes telomeric DNA (TTAGGG)n repeats. The overall goal of our work
was to establish human cancer models that can be used to design clinical trials with telomerase inhibitors. The objectives of this study were
(1) to set up a human breast cancer system that allows evaluation of the effects of telomerase inhibitors in cultured cells using a non-amplified
telomerase assay and (2) to test this system using two drugs (cisplatin and TMPyP4) that affect the telomerase expression in breast cancer
cells in culture. We first compared the telomerase activity in a variety of human breast cancer cell lines to that of other tumour types using a
new biotinylated-primer extension assay. Our method, based on a non-amplified primer extension assay shows the direct incorporation of 32P-
labelled nucleotides induced by telomerase on human telomeric primers. The 32P-dGTP labelled telomerase-extended 5¢-biotinylated
(TTAGGG)3 primer can subsequently be separated using streptavidin-coated magnetic beads. As compared to other non-amplified method,
we showed that this procedure improved the characterization and the quantification of the banding pattern resulting from telomerase
extension by reducing the radioactive background. Using this method, we observed that telomerase activity varies markedly in a panel of 39
human cancer cell lines. For example, MCF7 breast cancer cells in culture showed intermediate telomerase activity corresponding to
33.8 ± 3.4% of that of the HeLa cells (reference cell line). Similarly, the telomere length varied with each cell line (average: 6.24 ± 6.16). No
correlation between the level of telomerase and telomere length was observed, suggesting that a high processivity is not required to maintain
telomeres and that, in some cell lines, another mechanism of telomere elongation can maintain telomere length. From this study, we selected
MCF7 and MX1 models that showed reproducible telomerase activity and a relatively limited telomere length for the testing of potential
telomere–telomerase interacting agents. Using cisplatin and a new porphyrin-derived compound TMPyP4, we showed that our model was
able to detect a down-regulation of the telomerase activity in MCF7 cells in culture and in a human MX1 tumour xenografts. Based on these
results, a breast cancer model for evaluating telomerase and telomere interactive agents is proposed.
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biochemical studies, we experimented a new biotinylated-primer
extension assay for detecting telomerase activity. We showed that
this procedure reduces the radioactive background, improves the
sensitivity as compared to other conventional non-PCR methods,
and allows a better quantification of the telomerase signal as
compared to current conventional techniques (Sun et al, 1996,
1997; Thompson et al, 1996; Wheelhouse et al, 1998).
Advanced breast cancer represents a major challenge for the
development of new anticancer drugs (Fisher, 1996). Despite a rela-
tively high sensitivity to chemotherapy, the median duration of
survival of patients with metastatic breast cancer remains about 24
months (Piccart et al, 1995). Attempts to increase the dose intensity
of chemotherapy led to an increase in response rates but minimal
improvement in survival with most of the patients experiencing
recurrences within the first year after intensive chemotherapy. It has
previously been reported that telomerase is expressed during breast
epithelial cell immortalization (Shay et al, 1993a, 1995b).
Subsequent reports have indicated that advanced human breast
cancer cells overexpressed telomerase in 95% of cases (Hiyama et
al, 1996). In addition, there are data indicating an increase in the
telomerase activity between early and late breast cancer stages
(Hiyama et al, 1996; Bednarek et al, 1997; Tsao et al, 1997).
Therefore, telomerase and telomeres may represent interesting
targets for the development of new anticancer agents for patients
with advanced breast cancers (Raymond et al, 1996).
To date, there is little information regarding telomerase activity
using non-PCR-based techniques and attempting to correlate that
activity with telomere length in cell line that may be used for
testing new compounds against cultured human breast cancer
cells. Therefore, in this study we established the experimental
conditions for testing telomerase inhibitors in a human breast
cancer model. We first have developed our new biotinylated-
primer extension assay to measure telomerase activity in extracts
from human breast cancer cell lines and xenografts. Using this
method, we have investigated the level of functional telomerase
activity and attempted to correlate telomerase activity with
telomere lengths in human breast cancer cells. We subsequently
evaluated the effects of several antiproliferative agents on telo-
merase expression in culture, including cisplatin and a porphyrin
compound TMPyP4. Our data provide information that might
help with the design of preclinical and clinical studies using
compounds specifically designed to target telomerase and
telomeres in human breast cancer cells.
MATERIALS AND METHODS
Cell collections
Human cervix (HeLa), breast (oestrogen-sensitive MCF71,
oestrogen-resistant MCF7m, anthracyclin-resistant MCF7mdr,
p53 mutated MCF7-VHK4, MCF7-V4B, T47D, ZR75-1, BT20,
HS578t, HS578bst, MDA-MB-231, MDA-MB-330, MDA-MB-
435); prostate (LNCaP, DU145, TSUPr1, PC3); ovarian (OVCAR,
A2780, A2780DDP, SK-OV-3); colorectal (HT29, HS700T, DLD-
2, Colo201, HCT116); pancreatic (PANC-1); non-small-cell lung
(SK-MES-1, MV-522, HOP-62, SKLU, SKNH-SH, A549) and
small-cell lung (NCI-H522) cancer cell lines along with Burkitt’s
lymphoma (Raji, Daudi, Ramos); and acute lymphoblastic
leukaemia (CCRF-CEM) cell lines were successively tested in this
study. All cell lines but MCF7-VHK4, MCF7-V4B, A2780 and
A2780DDP were from American Tissue Culture Collection
(ATCC, Rockville, MD, USA). Mutant p53 MCF7-VHK4 cells
(substitution at codon 179 resulting in a mutation from histidine to
glutamine) derived from parental wild p53 MCF-7 (oestrogen and
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Figure 1 Biotinylated-primer extension telomerase assay. Telomerase
reaction was performed in the presence of biotinylated-(TTAGGG)3 primers
(A). Biotinylated primers extended by telomerase were captured by
streptavidin-coated magnetic beads (B). The extended primers attached to
the beads were separated and washed to remove free 32P-dGTP (C). The
extended primers were separated from the beads and then analysed by
electrophoresis (D)
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progesterone receptors positive) after transfection of the cDNA
derived from a mutated lung cancer cell line using a CMV
promoter for p53 expression, control MCF7-V4B cells containing
only the vector, and MCF7mdr were obtained from Dr R Elledge
(UTHSC, San Antonio, TX, USA). Parental A2780 and
A2780DDP (resistant to cisplatin) were obtained from Dr K
Scanlon (City of Hope, Duarte, CA, USA).
Normal cell were used as negative control. Normal human
RPMI 7666 lymphoblasts (ATCC) and MRC-9 lung fibroblast cell
lines (ATCC), and non-immortalized fibroblasts, endothelial and
epithelial cells from breast and prostate (all from Clonetic, San
Diego, CA, USA) were also tested in this assay. Normal and
cancer cells were grown in appropriate media in a humidified 37°C
incubator with 5% carbon dioxide.
Effects of cytotoxic drugs
The telomerase activity was evaluated in MCF7 cells cultured in the
presence of 5%, and 15% fetal bovine serum (FBS) or exposed to
antiproliferative agents including 4OH-cyclophosphamide (Sigma,
St Louis, MO, USA), doxorubicin (Sigma), cisplatin (Sigma), and
TMPyP4 (Gift from Laurence Hurley, Department of Pharmacy at
the University of Texas, Austin, TX, USA). To ensure that at least
10 million viable cells would be available for making telomerase
extracts after exposure to cytotoxic drugs, twenty
million cells were seeded in a T-150 flask and grown 24 h before
the addition of drugs. The cells were exposed to the drug for 2–
24 h, then washed and cultured in a drug-free media. The viability
was determined on a haemocytometer with Trypan blue. Ten
million control and drug-treated viable cells were serially aliquoted
for analyses at day 4, day 8 and day 15 after the drug removal.
In vivo experiments were performed in Harlan (nu/nu) athymic
mice (Sprague, Indianapolis, IN, USA) bearing transplantable
MX-1 human mammary tumour xenografts. MX-1 is a fast-
growing human tumour commonly used for the preclinical evalua-
tion of anticancer drugs (Plowman et al, 1997). MX-1 breast
cancer xenografts were previously shown to be predictive of
human response to new anticancer drugs (Plowman et al, 1997).
Care of the mice was in accordance with institutional and Federal
80 000
60 000
40 000
20 000
0
02 0 4 0 6 0
Number of cells (x 10
3)
r2 = 0.990813
30
20
10
0
0 1 53 04 56 07 59 0
Time (min)
HeLa
MCF-7
B
A
V
o
l
u
m
e
N
u
m
b
e
r
 
o
f
 
(
T
T
A
G
G
G
)
 
r
e
p
e
a
t
s
Primer
1st primer ext
2nd primer ext
3rd primer ext
4th primer ext
5th primer ext
6th primer ext
7th primer ext
8th primer ext
1
0
0
 
0
0
0
5
0
 
0
0
0
2
0
 
0
0
0
1
0
 
0
0
0
5
 
0
0
0
1
 
0
0
0
R
N
A
a
s
e
L
y
s
i
s
 
b
u
f
f
e
r
Number of HeLa cells
C
Figure 2 Telomerase activity in HeLa cell detergent extracts using a newly
designed biotinylated-primer extension telomerase assay. The assay allows
the direct measurement of the enzyme activity. (A) The activity level (volume)
was calculated by summation of integrated areas of the telomerase ladder
after background subtraction. The signal resulting from this assay is
proportional to the number of cells (i.e. the protein concentration in the
extract) and allows for the detection of a minimum of 1000 HeLa cells.
(B, C) The reduction of the radioactive background on the autoradiogram
allows for a clear visualization of the first primer extensions and the direct
visualization telomerase activity allows the determination of the number of
repeats added to the primer with time by telomeraseguidelines. Mice were treated with a single intraperitoneal injec-
tion of cisplatin at the dose of 9 mg kg–1, known to induce a
significant tumour response. At least five mice were used per
experimental group. Tumours were measured every 2 days and
mice were sacrificed when the tumour size was 50% of those from
the control group. Tumours from control and cisplatin-treated
groups were minced and repeatedly passed through metal sieves
with 40-mm mesh (EC Apparatus, St Petersburg, FL, USA) to
obtain a single-cell suspension. Specimens were washed twice in
McCoy’s 5A medium containing 5% horse serum (Sigma), 10%
heat-inactivated fetal calf serum (FCS; Hyclone, Logan, UT,
USA), 2 mM sodium pyruvate, 2 mM glutamine, 90 U ml–1 peni-
cillin, 90 mg ml–1 streptomycin and 35 mg ml-1 L-serine (all Gibco).
The viability of cells was determined on a haemocytometer with
Trypan blue.
Preparation of telomerase extracts
Only viable cells were used for telomerase experiments. Control
and drug-treated cells were processed side by side to ensure accu-
rate comparisons. For all samples, an aliquot containing 107 viable
cells was used for the telomerase extract. In all cases, cell samples
were cryopreserved at –196°C in liquid phase nitrogen, then
placed on ice (+4°C) just before telomerase extraction. Samples
containing suspensions of 107 cells as a single-cell suspension
were washed once in phosphate-buffered saline (PBS) (400 ml) and
pelleted at 10 000 g for 1 min at 4°C. Cells were subsequently
resuspended in 400 ml of ice-cold washing buffer containing
10 mM HEPES-KOH (pH 7.5), 1.5 mM magnesium chloride
(MgCl2), 10 mM potassium chloride (KCl) and 1 mM dithiothreitol
(DTT), then pelleted again at 10 000 g for 1 min at 4°C. Washed
cells were resuspended in 200 ml (106 cells per 20 ml) of ice-cold
lysis buffer containing 10 mM Tris–HCl (pH 7.5), 1 mM MgCl2,
1m M EGTA, 0.1 mM phenylmethylsulphonyl fluoride, 5 mM
b-mercaptoethanol, 1 mM DTT, 0.5% 3-[(3-cholamidopropyl)-
dimethyl-ammonio]-1-propanesulphonate (CHAPS), 10%
glycerol and 40 UI ml–1 RNAase inhibitor (Promega, Madison,
WI, USA). The suspension was incubated on ice for 30 min. This
usually permitted the lysis of 90–100% of cells. The lysate was
then transferred to polyallomer tubes (Beckman, Fullerton, CA,
USA) and spun at 100 000 g for 1 h at 4°C in a tabletop ultracen-
trifuge (Beckman). The supernatant was removed and the protein
concentration in the extracts was determined by the Bradford assay
(BioRad, Hercules, CA, USA) before all telomerase experiments.
The protein concentration ranged usually between 4 and
10 mg ml–1. When necessary (protein concentration < 4 mg ml–1),
telomerase extracts were concentrated using Microcon Microfilter
30 (Amicron, Beverly, MA, USA) to reach a final protein concen-
tration ranging from 4 to 10 mg ml–1. Then, the extract was quickly
stored at –80°C.
Telomerase assay
Telomerase activity was measured with our newly developed non-
amplified assay (Figure 1). An aliquot of the extract containing
10–15 mg of protein (2–5 ml of CHAPS extract) was used for each
telomerase assay. The telomerase extract was assayed in 20 ml of
reaction mixture containing 2 mM dATP, 2 mM dTTP, 0.6 mM a-
32P-dGTP and 1 mM 5¢-biotinylated (TTAGGG)3 primer, in the
presence of 1.428 ml of 14´ telomerase reaction buffer containing
0.7 M Tris KOAC, 14 mM MgCl2, 70 mM spermidine and 14 mM b-
mercaptoethanol. The solution was incubated for 1 h at 37°C for
telomerase extension of the primer. The reaction was terminated
by the addition of streptavidin-coated magnetic beads followed by
a magnetic separation of the bound primers. Telomerase extension
products bonded to the beads were washed several times with a
solution of 1 M sodium chloride (NaCl), in 10 mM Tris–HCl solu-
tion (pH 7.5) to eliminate non-incorporated a-32P-dGTP. The
washing process was facilitated by utilization of magnetic stands
(Dynal, New York, NY, USA). Subsequently, extended primers
were separated from the beads by incubation for 30 minutes in a
solution of 5.0 M guanidine–HCl at 90°C. Following ethanol
precipitation, telomerase reaction products were analysed by
electrophoresis in an 8% polyacrylamide denaturing gel. Gels
were dried on filter paper and developed by autoradiography on
an ultrasensitive Biomax MS film (Kodak, Rochester, NY, USA).
In the presence of processive telomerase activity, various
numbers of hexameric repeats are added to the 18-bp primer,
yielding a 6-bp incremental DNA ladder. Extracts from cells not
containing telomerase do not extend the primer. Enzyme activity
was quantified by autoradiograph followed by scanning on a
Molecular Dynamics PhosphoImager (Sunnyvale, CA, USA) and
the density of each band of the repeat ladder was determined using
ImageQuant software (Molecular Dynamics, Sunnyvale, CA,
USA).
HeLa cells have been shown to have a high and reproducible
telomerase activity in the conventional telomerase assay, and
therefore that cell line was used as a positive control and for
normalization of the level of telomerase activity in our assay. Total
activity was expressed as a percentage of that in HeLa cell extract
(positive control) after normalizing for protein content.
Experiments in breast cancer cell lines were performed at least
in duplicate. A sample was considered positive for telomerase
activity if the signal was abrogated by pre-incubation with
RNAase I (Worthington Biochemical Corp., Freehold, NJ, USA).
Extracts were considered negative if no extension was detected
after 7 days of exposure to ultrasensitive Biomax-MS films
(Kodak) using two Biomax-MS intensifying screens (Kodak).
Telomere length analysis
Genomic DNA was prepared by incubating cell pellets in 2 ml of
lysis buffer (0.1 M NaCl, 10 mM Tris (pH 8.0), 25 mM EDTA
(pH 8.0), 0.5% sodium dodecyl sulphate (SDS), and 0.1 mg ml–1
proteinase K for 1 h at 37°C, followed by phenol extraction and
ethanol precipitation. DNA pellets were resuspended in a solution
containing 10 mM Tris (pH 7.6), 1 mM EDTA (pH 8.0) and restric-
tion digests were done with Sau 3A1 in southern blots with
hybridization to a TTAGGG telomeric probe. Approximately
10 mg of digested DNA per lane was loaded onto a 0.8% agarose
gel. Southern blotting was performed by standard methods, and
blots were hybridized with a-32P-labelled oligonucleotide
(TTAGGG)3 at 42°C for 18 h. Prior to restriction digestion, a
portion of each DNA sample was electrophoresed to verify its
integrity. Telomere lengths were measured with an ultrascan
densitometer, with the center of the peak taken as the mean telo-
meric restriction fragment length. For several data sets, telomere
lengths were also calculated as previously described following
scanning of the southern blot autoradiograms with a digital
scanner. Experiments were performed at least in duplicate.
Telomerase activity and telomere length in breast cancer cells 1335
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RESULTS
Telomerase activity in conventional primer extension
telomerase assay
To confirm the linearity of our biotinylated-primer extension
telomerase assay (Figure 1), we initially performed a dilution
experiment with HeLa cells. We observed a linear relationship
between the number of cells in the extract and the CHAPS-extract
protein concentration in the telomerase reaction (data not shown).
Telomerase activity was readily detectable in samples containing
at least 500–1000 HeLa cells.
The level of telomerase was proportional to the protein concen-
tration, i.e. to the number of cells in the extract (Figure 2A). As
shown in Figure 2C, the reduction of the radioactive background
on the autoradiogram allows for a clear visualization of the first
primer extension and the number of TTAGGG-repeats added by
telomerase with time (Figure 2B). Assaying the same sample at
three different occasions, led to 4% variation of the signal demon-
strating a good reproducibility of this method.
As expected, the telomerase activity was abolished in RNAase I
pretreated samples (Figure 2C) as well as in samples heated at
95°C for 10 min prior to the telomerase reaction (data not shown).
Using the procedure described above, the protein concentration in
cancer cell extracts typically ranged from 6 to 8 mg ml–1. A HeLa
cell extract that was aliquoted, was quickly frozen (–80°C), and
was stable for at least five freeze–thaw cycles and for more than 6
months which ensured comparison between experiments.
Using this method, we observed a 3-band pattern for each
telomerase extension (Figure 2C). This was never reported before
using other methods for the measurement of telomerase activity.
However, conventional methods and the TRAP assay for telo-
merase measurement either do not allow the direct visualization of
the banding pattern due to either a lack of sensitivity due to a high
background (conventional assay) or do not measure the signal
directly resulting from the incorporation of nucleotides due to the
amplification process. Our method for telomerase measurement
that used a long polyacrylamide denaturing gel similar to those
used for sequencing gels allows the discrimination of each incor-
porated radiolabelled nucleotide. Since there is no amplification,
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Figure 3 Telomerase activity and telomere lengths in breast cancer cells. The biotinylated-primer extension telomerase assay was performed using extracts
containing 100 000 cell-equivalents. The telomerase activity in cell lines was compared to that of HeLa cells (% of HeLa cell activity). The telomerase activity
varied markedly with cell lines, but no significant difference in telomerase was observed between breast cancer and other tumour types (A). Breast cancer cell
lines MCF7 and MX1 showed high telomerase activity while no telomerase activity was detected in BT20 (B). The telomere length in breast cancer cell line was
similar to that of a panel of cell lines from a large variety of tumour types (C). There was no significant correlation between telomere length and telomerase
activity. For example, BT20 that shows low telomerase activity with our method had maintained telomere length suggesting that mechanisms other than
telomerase can extend the telomeric region of DNA in this particular cell line (D)the observed banding directly results from the direct incorporation
of  32P-radiolabelled dGTP on the biotin-(TTAGGG)3 primer.
Therefore, this 3-band pattern suggests that telomerase pauses
after each 32P-radiolabelled dGTP incorporation.
Telomerase activity in human breast cancer cell lines
Comparing telomerase signals in a variety of 39 human cancer cell
lines to that of HeLa cells, we observed that the level of telomerase
varied markedly from cell line to cell line (31.8 ± 24.9%, range:
0–100, Figure 3A). No significant difference in telomerase activity
was observed in individual cell lines taken at different passages
under similar standard growth conditions (data not shown).
Similarly, the doubling time and tumorigenicity of individual cell
lines did not correlate with telomerase activity (data not shown).
With our method, only three out of the 39 cell lines studied (7.7%,
BT20, SKLU and ZR75-1) did not show any telomerase activity.
Normal fibroblasts, normal endothelial and normal epithelial cells at
early passages did not show processive telomerase activity (data not
shown). In this study, the average telomerase activity in breast
cancer cell lines was 19.6 ± 12.7% (range: 0–35.75) versus
37.8 ± 27.4% (range: 0–100) in other types of human cancer cell
lines. We showed that MCF7 breast cancer cells expressed a high
level of telomerase activity (33.8 ± 3.4%, range: 30–36.6) compared
to other breast cancer cell lines (Figure 3A, B). Interestingly, the
level of telomerase in MCF7 was very stable from one experiment
to another. We further showed that oestrogen-independent,
oestrogen-dependent, doxorubicin-resistant and p53-mutated
MCF7 cells expressed similar levels of telomerase activity (data not
shown). Interestingly, using our method, we did not detect any
significant telomerase activity in BT20 breast cancer cells in several
experiments (Figure 3B). This cell line was further tested using the
TRAP assay, which allow the detection of telomerase activity in this
cell line. This suggests that a low level of telomerase is present in
this cell line. However, using our assay we can assume that the level
of telomerase in BT20 is at least 1000 times lower than in MCF7.
Telomere lengths in human breast cancer cell lines
We showed that telomere lengths varied with cell line (average:
6.24 ± 6.16 Kbp). No significant difference in telomere length was
observed in individual cell lines taken at different passages under
similar standard growth conditions. The average telomere length in
human breast cancer was 5.1 ± 1.1 Kb versus 7.5 ± 6.7 Kb in other
tumour types (Figure 3C). In the MCF7 cell line, which showed
processive telomerase activity, the telomere length was 5.2 ± 1.1
kbp (range: 3.8–6.63, Figure 3D). In the BT20 breast cell line,
which did not show processive telomerase activity, the average
telomere length was 4.3 ± 0.03 Kb (range: 4.2–4.3). No correlation
between the telomere lengths and the levels of telomerase was
observed suggesting that high processivity of the telomerase
enzyme is not essential for telomere maintenance. Moreover, while
the level of telomerase activity was very low in BT20 cells, the
telomere length was comparable to that of other breast cancer cells
with higher telomerase activity (Figure 3D). This suggests that a
mechanism other than telomerase expression may be responsible
for telomere elongation in this particular cell line.
Effects of drugs on telomerase activity in vitro
The effects of cytotoxic drugs were tested in MCF7 cells. The
growth of MCF7 cells in the presence of drugs was determined
prior to the telomerase experiment to identify concentrations
inducing about 25%, 50% and 75% growth inhibition. The cells
that were exposed to concentrations of 4OH-cyclophosphamide
below 0.5 mM for 1 h (IC50) and those exposed to concentrations of
doxorubicin below 0.01 mg ml–1 for 1 h (IC50) had no significant
decrease in telomerase activity (data not shown). Higher concentra-
tions often induced dramatic cytotoxicity that did not allow us to
maintain cells in culture. We observed 48.8%, 50.8% and 81.4%
decrease of MCF7 cell growth after a 4-day exposure to 0.1, 1.0 and
10.0 mM cisplatin respectively (Figure 4A). The effects of cisplatin
on the cell growth was transient with a quick recovery
by day 8 after exposure. As shown in Figure 4A, the telomerase
activity was significantly reduced at day 4 in cells exposed to these
concentrations of cisplatin. Telomerase inhibition closely followed
the cell growth with recovery at day 8 after cisplatin exposure. In a
cell-free system, cisplatin did not inhibit telomerase suggesting
indirect effects in cells (data not shown). Because cisplatin is
known to bind to guanine-rich regions of DNA, we subsequently
attempted to determine whether it could affect telomere stability. In
a cell-free system, we observed that incubation of the telomeric
primer for more than 12 h with cisplatin was associated with primer
degradation (data not shown). However, in cultured cells, attempts
to maintain MCF7 cell growth in the presence of cisplatin at
concentrations ³ 0.1 mM were associated with dramatic cytotoxi-
city. Protracted exposure to concentrations of cisplatin < 0.1 mM did
not significantly reduce telomerase activity and was not associated
with telomere shortening (data not shown).
The cytotoxic effects of TMPyP4 on telomerase activity was
investigated in MCF7 cells in culture. TMPyP4 is a fluorescent
compound that rapidly accumulates into the cells and concentrates
into the nucleus few hours after incubation. No significant antipro-
liferative effects were observed at concentration ranging from 1 to
50 mM and a 30% growth inhibition was observed at 100 mM. As
shown in Figure 4C, TMPyP4 reduced telomerase activity at
concentration ranging from 1 to 100 mM in vitro. However, no
significant reduction of the telomere length was observed after 15
days of exposure to TMPyP4 (data no shown).
In vivo model for the study of telomerase activity
We observed that the level of telomerase and telomere length of
MCF7 human tumour xenografts in mice was identical to that
observed in cells in culture (data not shown). Moreover, MX1
breast cancer xenografts commonly used for the preclinical evalu-
ation of anticancer drugs showed a high level of telomerase corre-
sponding to 35.75 ± 7.15 (range: 28.6–42.9%) of that of HeLa
cells. The average telomere length in MX1 cells was 7.5 ± 0.5 Kb
(range: 7–8). Extracts from mice leucocytes, gut, liver and skin did
not express telomerase activity in our assay (data not shown).
We subsequently evaluated the effects of cisplatin on telomerase
activity in MX1 breast cancer xenografts in mice. As shown in
Figure 4B, 9 mg kg–1 cisplatin was very effective in inducing
tumour shrinkage in MX1 xenografts. To evaluate the effects of
cisplatin on telomerase activity in xenografts, we sacrificed mice
immediately before and 5 days after cisplatin treatment. At the
time of sacrifice both group had about the same tumour volume.
Figure 4B shows that a decrease in telomerase activity can be
observed 5 days after treatment with cisplatin in MX1 breast
cancer xenografts in mice. Few mice that did not show response to
therapy had no decrease in telomerase activity as compared to the
control (data not shown).
Telomerase activity and telomere length in breast cancer cells 1337
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DISCUSSION
In this study we applied a new method for investigating telomerase
activity in breast cancer cells in culture. Our method allows the
direct measurement of telomerase activity through incorporation
of a labelled nucleotide. The use of a 5¢-biotinylated primer allows
for the capture of telomerase-extended primers using strepta-
vidine-coated magnetic beads. Then, using magnets that allow the
separation of extended primers, residual 32P-dGTP can be washed
out and the signal resulting from the incorporation of labelled
dGTP onto the primer becomes distinguishable from the back-
ground. The utilization of excess of streptavidine-coated magnetic
beads allows for the recovery of the biotinylated primers extended
by telomerase. Based on our data, the TRAP-assay which detects
telomerase activity in fewer than 10 cells over a million, is
undoubtedly more sensitive than our method, which requires
500–1000 cells to detect telomerase activity. However, the TRAP
assay has several limitation for whom wanting to quantify telo-
merase inhibition. Those limitations have been described by Kim
et al (1994) in the original publication then re-evaluated by several
other authors (Holt et al, 1996) leading to subsequent improve-
ment of the TRAP-method. Major limitations of the TRAP assay
are related to quantification and PCR-derived artifacts. There have
been several attempts to improve the quantification of telomerase
activity using internal controls, using standard telomerase-positive
cell lines, and using a quantification control in the commercially
available TRAP assays. When we started to investigate the effects
of telomerase inhibitors, the quantification of telomerase activity
was our primary concern. Problems potentially resulting from the
interaction of our compounds with the TS-primer, the CX primer
and the Taq polymerase were likely to result in false-positive or
false-negative results. Moreover, false-positive results that might
result from primer dimer artifacts present in the TRAP assay might
be favoured by DNA-interacting agent that stabilized unspecific
primer dimer formations. In addition, synthetic primers used as
substrates for telomerase in PCR-methods do not behave like
(TTAGGG) sequences when exposed to some alkylating or inter-
calating agents designed to bind G-quartets such as TMPyP4.
Since, in our lab, we were investigating G-quadruplex interacting
agents, it was highly preferable to consistently use the same
method for telomerase measurement from the biochemical reac-
tions to the in vivo assay. We observed that our method provides a
significant advantage over current PCR-based method by the fact
that it is a one-step reaction that showed on the gel the direct incor-
poration of nucleotides in the telomeric primer and by displaying
elongation products that unlike the TRAP assay does represent the
processivity of the enzyme. In addition, our method uses the
human TTAGGG-sequence as a template for telomerase reaction
and might be considered for investigating G-quadruplex inter-
acting compounds. Of interest, our method prevents a direct inter-
action between the tested compound and the TS-primer, the
CX-primer and the Taq polymerase. In addition, this method
avoids primer dimer artifacts.
However, limitation of our method should also be underlined.
As mentioned above, the sensitivity of our method is undoubtedly
lower than that of the TRAP assay (Kim et al, 1994; Holt et al,
1996) but higher than that of other conventional primer extension
protocols currently used (Shay et al, 1994). Therefore, due to the
lack of sensitivity, this method is unsuitable for the measurement
of telomerase using small tissue specimens that contain a limited
number of cells. In addition, this method requires a larger amount
of 32P dGTP as compared to the TRAP assay, require basic knowl-
edge in molecular biology, and need more practice than the TRAP
assay that is now available as a kit. Therefore, our method could
not be recommended for routine clinical detection of telomerase in
specimens from patients, but instead could be used for laboratory
experiments in which the experimental setting allows use of a large
number of cells.
Several previous reports have indicated that telomerase is
expressed in breast cancer and may play an important role in
carcinogenesis and tumour progression (Shay et al, 1993b, 1995b;
Hiyama et al, 1996; Bednarek et al, 1997; Tsao et al, 1997).
Therefore, inhibition of telomerase may represent a new strategy
against this particularly frequent malignancy. However, few models
have been specifically developed to study the biological effects of
those inhibitors in human cancer cells. Chadeneau et al (1995) have
reported telomerase activity using the TRAP assay in mammary
tumour cells from transgenic mice overexpressing the neu gene.
However, Prowse et al (Prowse et al, 1993; Prowse and Greider,
1995) have shown that, while human telomerase can processively
synthesize long TTAGGG repeats in vitro, the mouse telomerase
appears to be much less processive. Those differences in proces-
sivity may be related to differences in telomerase enzyme protein
structure and function and therefore suggest that mouse telomerase
may not be suitable for the study of compounds specifically
designed to target human telomerase (Raymond et al, 1996).
Moreover, based on previously published data (Chadeneau et al,
1995) and in our experience, the telomere lengths in transgenic
mouse tumour cells are usually 10–100-fold longer than that of
human cancer cells. Therefore, a certain number of cell divisions,
which may exceed the average life time of mice, may be required
before telomere shortening becomes manifest phenotypically in
transgenic mice. For these reasons transgenic models may not be
suitable for preclinical evaluation of new compounds designed to
target human telomerase and telomeres in advanced cancer models.
In this study, we showed that telomerase activity varies
markedly between different human cancer cell lines. However,
there was no correlation between the activity of the enzyme and
the telomere length. Authors have reported that immortalized cells
can maintain their telomeres by other, but still unidentified, mech-
anisms that do not involve telomerase (Bryan et al, 1995). We
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showed that telomerase-negative immortalized cells appear infre-
quently (less than 8% in our study). We showed that breast cancer
cell lines are attractive models for future evaluation of compounds
that target telomerase and telomeres. For example, the high level of
telomerase in MCF7 and MX1 cells and the relatively short
telomere lengths represent reasonable parameters for the testing of
new compounds. MX1 is a fast-growing human tumour commonly
used for the preclinical evaluation of anticancer drugs but, unfortu-
nately, does not grow in vitro (Plowman et al, 1997). MCF7 cancer
cells grow in vitro but is a slow-growing tumour in vivo. Moreover,
MCF7 express CEA biological marker and offer a large variety of
derived counterparts such as doxorubicin-resistant, hormone-
refractory and p53-mutated cell lines with similar telomerase
activity that can be subsequently evaluated to closely determine in
which situation new compounds may have optimal activity.
Together, MX1 and MCF7 provide an interesting human breast
cancer model for the testing of potential telomere–
telomerase interactive agents in vitro and in vivo.
Predictive mathematical simulations indicate that after inhibition
of telomerase a relatively long period of time corresponding to about
20–30 cell divisions would be necessary for telomerase inhibitors to
induce a dramatic telomere shortening and chromosomal instability
(Vojta and Barret, 1995). Such a number of cell divisions is theoret-
ically sufficient to increase the tumour mass by 1000 times in
patients and is certainly sufficient to kill the host (Harley et al, 1992,
1994; Harley and Villeponteau, 1995). This lag time is incompatible
with life for a patient with a rapidly growing human breast cancer.
Therefore, the clinical development of telomerase inhibitors will
need to integrate this lag time period into any new drug development
strategy (Raymond et al, 1996). Such a strategy may incorporate
conventional chemotherapy in order to reduce the tumour size
before the utilization of telomerase inhibitors in patients with
minimal residual disease after debulking induction chemotherapy
(Sharma et al, 1997). To determine whether anticancer agents which
can be used to initially reduce the tumour can also modulate telom-
erase activity, we evaluated the effects of some classic agents against
MCF7 breast cancer cells. We investigated the effects of doxo-
rubicin and 4OH-cyclophosphamide, which are considered major
anticancer drugs in the treatment of patients with advanced breast
cancers, on telomerase activity and telomere lengths. Since recent
reports also indicate that cisplatin may be an effective inhibitor of
telomerase (Burger et al, 1997), we subsequently tested the effects
of cisplatin on telomerase activity in breast cancer cells in vitro and
in vivo. We observed that various concentrations of cisplatin and
high concentration of cyclophosphamide and doxorubicin can
decrease the telomerase activity. Our results are consistent with
other reports indicating that cytotoxic effects of anticancer drugs can
be monitored by measuring telomerase activity (Burger et al, 1997;
Faraoni et al, 1997). High concentrations of cytotoxic drugs are
likely to affect telomerase expression by a non-specific inhibition of
DNA, RNA and/or protein synthesis. Interestingly, we observed that
relatively low concentrations of cisplatin, which transiently inhibit
the cell growth, were also able to transiently down-regulate telo-
merase. We showed that this inhibition was not due to direct inter-
action between cisplatin and the telomerase enzyme. However,
telomerase inhibition induced by cisplatin was only transient and
despite the potential of cisplatin to bind G-rich DNA region, long-
term exposure to low concentrations of cisplatin was not associated
with telomere shortening. Unlike HeLa cells (Ishibashi et al, 1998),
telomeres of MCF7 cells do not shorten and degrade after cisplatin
exposures. Recent reports indicate that cisplatin indirectly effects
telomerase in cancer cells through the interaction with a telomerase-
RNA encoding gene region (Burger et al, 1997). Combined, these
results suggest that telomerase can be temporarily down-regulated in
cancer cells after high-dose chemotherapy. To investigate whether
telomerase can be effectively down-regulated in tumours, we moni-
tored the telomerase activity in mice bearing MX1 breast cancer
xenografts after treatment with active doses of cisplatin. We
observed that the tumour shrinkage induced by cisplatin in this
model was associated with a significant decrease of the telomerase
activity. These results suggest that classical chemotherapy may not
only induce tumour shrinkage in human cancer but may also tran-
siently inhibit telomerase. In addition, we showed that a compound
with mild antiproliferative effects such as TMPyP4, specifically
designed to interact with telomeres and telomerase in vitro (Sun et
al, 1997; Wheelhouse et al, 1998), can induce telomerase inhibition
in cultured cells. However, since no significant telomere shortening
was observed after a 14-day exposure, it is likely that those
compounds will need very prolonged exposure and/or co-exposition
to other telomere interactive agents to shorten telomeres. Our results
suggest that advanced breast cancer may be a valid preclinical and
clinical tumour for testing of new drugs that target telomerase.
Moreover, our data support the utilization of a high-dose debulking
chemotherapy prior to treatment with telomerase inhibitors in breast
cancer to accelerate telomerase inhibition and overcome the lag time
problem expected with telomerase inhibitors.
In summary, we have implemented a new method utilizing a
non-amplified telomerase assay to measure the level of telomerase
in breast cancer cells. Using this method, we showed that breast
cancer is a reasonable human tumour model for the study of telo-
merase inhibitors that are being developed (Izbicka et al, 1997).
Furthermore, our data suggest that pretreatment with conventional
chemotherapeutic agents may be incorporated in the setting of
preclinical and clinical trials with new telomerase inhibitors to
both rapidly shrink the tumour and reduce the telomerase activity
in advanced human breast cancers.
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